Financial Contrast: Traws Pharma (TRAW) & Its Rivals

Traws Pharma (NASDAQ:TRAW – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Traws Pharma to related businesses based on the strength of its earnings, profitability, valuation, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 8.7% of Traws Pharma shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Traws Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Traws Pharma N/A -23,868.92% -165.52%
Traws Pharma Competitors -2,398.26% -203.62% -15.08%

Valuation and Earnings

This table compares Traws Pharma and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Traws Pharma $2.79 million $9.17 million -0.15
Traws Pharma Competitors $18.55 billion $3.23 billion 561.62

Traws Pharma’s rivals have higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Traws Pharma has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Traws Pharma’s rivals have a beta of -0.04, indicating that their average stock price is 104% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Traws Pharma and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma 1 4 0 0 1.80
Traws Pharma Competitors 7845 13797 25812 1039 2.41

Traws Pharma presently has a consensus target price of $1.00, suggesting a potential upside of 284.62%. As a group, “Pharmaceuticals” companies have a potential upside of 23.66%. Given Traws Pharma’s higher possible upside, equities analysts clearly believe Traws Pharma is more favorable than its rivals.

Summary

Traws Pharma rivals beat Traws Pharma on 10 of the 13 factors compared.

Traws Pharma Company Profile

(Get Free Report)

Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.

Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.